BFM
GBT

Boothbay Fund Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Boothbay Fund Management’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-213
Closed -$923K – 1906
2020
Q4 		$923K Buy
+213
New +$10.5K 0.03% 521
2020
Q3 		– Sell
-290
Closed -$1.83M – 1312
2020
Q2 		$1.83M Buy
290
+223
+333% +$15.3K 0.13% 215
2020
Q1 		$342K Sell
67
-124
-65% -$8.31K 0.03% 539
2019
Q4 		$1.52M Sell
191
-245
-56% -$14.5K 0.13% 214
2019
Q3 		$2.12M Hold
436
– – 0.19% 123
2019
Q2 		$2.29M Buy
436
+142
+48% +$8.16K 0.21% 126
2019
Q1 		$1.56M Buy
294
+72
+32% +$3.54K 0.15% 155
2018
Q4 		$911K Sell
222
-6
-3% -$225 0.13% 163
2018
Q3 		$866K Sell
228
-235
-51% -$10.4K 0.09% 236
2018
Q2 		$2.09M Buy
+463
New +$21.1K 0.18% 90

Other funds holding GBT

BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Boothbay Fund Management's GBT Position: Q4 2022 in Review

Boothbay Fund Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 43,670 shares — an estimated $2.97M sold.

Boothbay Fund Management first reported a position in GBT in Q4 2018 and held it in 4 quarters. The position peaked at $2.97M in Q3 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

  • Boothbay Fund Management reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
  • Boothbay Fund Management sold 43,670 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $2.97M.
  • Boothbay Fund Management first reported a position in Global Blood Therapeutics, Inc. in Q4 2018 and held it in 4 quarters.
  • Boothbay Fund Management's Global Blood Therapeutics, Inc. position peaked at $2.97M in Q3 2022.
  • 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on Boothbay Fund Management's 13F filing for Q4 2022, filed 14 Feb 2023.